{"filings":[{"id":471637,"accession_number":"0001140361-26-021672","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-05-15T20:30:24+00:00","items":["5.07"],"status":"ready","headline":"Viatris shareholders elect all 13 directors, approve executive compensation, ratify Deloitte & Touche","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; votes For ranged from 798.5M (JoEllen Lyons Dillon) to 871.8M (Elisha Finney).","Non-binding advisory vote on 2025 executive compensation approved: 846.4M For, 26.9M Against.","Ratification of Deloitte & Touche LLP as independent auditor for FY2026 approved: 969.3M For, 27.7M Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95487,"accession_number":"0001792044-26-000025","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q1 revenues $3.5B (+8% YoY), adj. EBITDA $1.0B, reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.5B, up 8% reported and 3% operational vs Q1 2025.","US GAAP net earnings $176M; Adjusted EBITDA $1.0B, +10% operationally.","Reaffirms 2026 financial guidance; expects >$2.5B cash available for deployment.","Launched Effexor for generalized anxiety disorder in Japan; pipeline milestones progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":3517000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95486,"accession_number":"0001140361-26-018887","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris CFO Theodora Mistras to depart; Paul Campbell appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Financial Officer Theodora Mistras voluntarily ceases role effective May 8, 2026, to pursue another professional opportunity.","Paul Campbell, Chief Accounting Officer and Corporate Controller, appointed interim CFO effective May 8, 2026.","Mistras will remain employed through May 22, 2026, for transition; not eligible for severance or equity vesting.","Mistras eligible for pro rata bonus for 2026 based on actual performance, subject to release and restrictive covenants.","Viatris to release Q1 2026 results on May 7, 2026, and host conference call at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108605,"accession_number":"0001792044-26-000010","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"Viatris Q4 2025 revenue $3.7B, FY $14.3B; announces restructuring with $700-850M charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $3.7B, FY2025 total revenues $14.3B; met or exceeded all 2025 guidance metrics.","Returned over $1B to shareholders in 2025; expects balanced capital allocation for 2026.","Global workforce reduction of up to ~10%; total pre-tax restructuring charges $700-850M.","Enterprise-wide strategic review completed; expects $650M cost savings with up to $250M reinvestment over 3 years.","Anticipates regulatory decisions for six product candidates and multiple pipeline milestones in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":14299900000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108604,"accession_number":"0001140361-26-003477","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viatris Chief Legal Officer Brian Roman departs Feb 9; Matthew Maletta appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Roman to cease as Chief Legal Officer on Feb 9, 2026; remains employee until April 1 for transition.","Roman eligible for separation payments: base salary plus target bonus and pro rata 2026 bonus, subject to release.","Matthew Maletta joins as Chief Legal Officer on Feb 9; previously EVP, Chief Legal Officer and Secretary of Endo, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125056,"accession_number":"0001140361-25-044706","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viatris to sell Biocon Biologics stake for $815M in cash and equity from Biocon Limited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Viatris receives $400M cash and $415M in newly issued Biocon Ltd shares for Biocon Biologics convertible preferred equity.","Biosimilars non-compete restrictions end immediately ex-U.S., by Nov 2026 in U.S., accelerating Viatris' market access.","Transaction expected to close in Q1 2026; subject to closing conditions and taxes; Citi acted as financial advisor.","CEO Scott A. Smith says deal provides significant optionality and advances Viatris' strategic evolution.","Biocon shares subject to six-month lock-up; consideration subject to related taxes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125055,"accession_number":"0001140361-25-044544","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Viatris shareholders elect 13 directors, approve say-on-pay, ratify Deloitte at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected; lowest support was JoEllen Lyons Dillon with 779M for vs 72M against.","Advisory vote on 2024 named executive officer compensation approved: 831M for, 38.6M against.","Ratification of Deloitte & Touche as independent auditor approved with 963.7M for, 25M against.","Broker non-votes of ~117M shares on director election and say-on-pay had no effect on outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125052,"accession_number":"0001140361-25-044541","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K/A","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viatris appoints David Simmons to Compensation and Science & Technology Committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Simmons added to Compensation Committee effective after 2025 annual meeting.","Also appointed to Science and Technology Committee effective post-2025 annual meeting.","Amendment to Aug 4 2025 8-K that reported Simmons' board appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125054,"accession_number":"0001792044-25-000042","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q3 results in line, raises FY guidance; acquires Aculys Pharma; NDA for estrogen patch","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total revenues for Q3 2025 in line with expectations; raising and narrowing 2025 guidance for revenues, adjusted EBITDA, adjusted EPS.","Submitted NDA for low-dose estrogen weekly patch; advancing pipeline.","Acquired Aculys Pharma, gaining rights to Pitolisant (Japan) and Spydia (Japan & Asia-Pacific).","Year-to-date capital return >$920M, including $500M in share repurchases.","CEO cites strong execution and strategic review for sustainable growth in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":10596300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125053,"accession_number":"0001140361-25-039269","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.03","5.08","8.01","9.01"],"status":"ready","headline":"Viatris amends bylaws on proxy access timing, sets 2026 annual meeting for May 15","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws, effective October 24, 2025, revising Section 2.16(b) on proxy access nomination notice.","2026 annual meeting of shareholders scheduled for May 15, 2026; details in upcoming proxy statement.","Shareholder director nominations for 2026 meeting must be received between Jan 15 and Feb 14, 2026.","Proxy access nominations (3% holder for 3+ years) due by Jan 15, 2026; early window opens Dec 16, 2025.","Rule 14a-8 proposals for 2026 proxy must be received by Nov 24, 2025; universal proxy notice deadline Mar 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141750,"accession_number":"0001792044-25-000031","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q2 revenues beat expectations; reaffirms 2025 guidance, returns $630M+ to shareholders","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q2 total revenues exceeded company expectations; specific figures not disclosed.","Returned over $630M of capital to shareholders YTD, including $350M in share buybacks.","Late-stage pipeline momentum with positive Phase 3 data readouts from five studies.","Reaffirmed all 2025 guidance metrics; expects top half of range for total revenues and adjusted EPS.","FY 2025 operating cash flow guidance: $2.2B–$2.5B (midpoint ~$2.35B)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":6836400000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141749,"accession_number":"0001140361-25-028739","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints ex-PPD CEO David Simmons to board; board expands to 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Simmons appointed independent director effective August 4, 2025; board size increased from 14 to 15.","Simmons was Chairman/CEO of PPD (led to $17.4B sale to Thermo Fisher), 15+ years at Pfizer, CEO of Caliber Holdings.","No related-party transactions or arrangements per Item 404(a) of Regulation S-K.","Committee assignments pending; compensation consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159645,"accession_number":"0001792044-25-000016","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reaffirms 2025 outlook after Q1 results; returns >$450M to shareholders YTD","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total revenues in Q1 2025 in line with expectations; three positive Phase 3 data readouts achieved.","Year-to-date share repurchases over $300 million; total capital returned >$450 million.","2025 net cash from operations guided at $2.2-2.5 billion (midpoint ~$2.35B); outlook reaffirmed.","CEO cites pipeline progress and operational execution as drivers of confidence in full-year guidance.","Full Q1 financial details not provided in this excerpt; reliance on summary statements."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":3254300000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159644,"accession_number":"0001140361-25-017356","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints Frank D'Amelio and Michael Severino to Board; Rajiv Malik and Harry Korman to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank D'Amelio (former Pfizer CFO) and Michael Severino (Tessera CEO) appointed independent directors effective May 5, 2025.","Rajiv Malik and Harry Korman will retire at end of current terms in December after the 2025 Annual Meeting.","D'Amelio appointed to Finance Committee; Severino to Science and Technology Committee.","Both new directors bring pharmaceutical and executive experience; company cites ongoing board refreshment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178023,"accession_number":"0001792044-25-000004","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reports FY2024 revenue $14.7B, GAAP net loss $634M, adj EPS $2.65; guides 2025 share buybacks $500-650M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenues $14.7B; GAAP net loss $634M ($0.53 diluted loss); adjusted EPS $2.65.","Free cash flow $2.0B (incl. ~$650M transaction costs) exceeded guidance; repaid $3.7B debt; leverage 2.9x.","New product revenues $582M; 2025 expects six Phase 3 readouts for selatogrel, cenerimod, sotagliflozin.","2025 guidance includes Indore facility warning letter/import alert impact; enterprise cost review initiated.","Plans $500M-$650M share repurchases in 2025; returned $825M to shareholders in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":14739300000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194707,"accession_number":"0001193125-24-272562","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Viatris shareholders reject say-on-pay proposal; approve 49M share increase for equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding say-on-pay proposal failed with 49.23% in favor (458.9M against, 5.4M abstain).","Shareholders approved amendment to 2020 Stock Incentive Plan increasing authorized shares by 49 million.","All 12 director nominees elected; JoEllen Lyons Dillon received lowest support (737.8M for, 167.7M against).","Deloitte & Touche ratified as auditor for FY2024 with 962.95M votes in favor.","Broker non-votes of ~115M shares reported on proposals 1, 2 and 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194706,"accession_number":"0001792044-24-000031","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q3 2024: Revenue $3.8B, GAAP EPS $0.08, Adjusted EPS $0.75, Repaid $1.9B Debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.8B, operational revenue growth ~3% on divestiture-adjusted basis; new product revenues $133M.","GAAP net earnings $95M ($0.08 diluted EPS); adjusted EBITDA ~$1.3B (+4% divestiture-adjusted); adjusted EPS $0.75 (+6%).","Repaid ~$1.9B debt including make-whole call; expects to reach ~3.0x gross leverage target by year-end.","Entered exclusive licensing agreement with Lexicon for sotagliflozin outside U.S. and Europe.","Reaffirms 2024 full-year outlook: ~2% revenue growth on divestiture-adjusted operational basis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11211200000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211008,"accession_number":"0000950157-24-001314","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Viatris enters $3.5B revolving credit facility, replacing $4B revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $3.5B facility includes $300M LC subfacility and $175M swingline sublimit.","Facility matures in five years; leverage covenant max 3.75:1 as of each fiscal quarter end.","Initial interest rate SOFR + 1.10% or base rate + 0.10%; facility fee 0.15%.","Proceeds used for general corporate purposes and to repay existing $4B facility.","Viatris can seek added commitments if pro forma leverage compliance is maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211007,"accession_number":"0000950157-24-001164","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viatris launches cash tender offers for up to ~$1.8B in notes due 2025-2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Any and all of $750M 1.650% Senior Notes due 2025 (Viatris) and €500M 2.125% Senior Notes due 2025 (Mylan) sought.","Up to $450M of $2.25B 3.950% Senior Notes due 2026 (Utah Acquisition) with $30/$1,000 early tender premium.","Any and All Tender Offers expire Sept 10, 2024; Maximum Tender Offer expires Oct 2, 2024; early tender deadline Sept 17.","If less than all Viatris 2025 notes tendered, company may satisfy and discharge indenture; Mylan may redeem remaining.","Barclays, Citigroup, and J.P. Morgan act as dealer managers for the offers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211006,"accession_number":"0001792044-24-000022","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q2: GAAP net loss $326M, adjusted EPS $0.69 up ~3%; raises new product revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.8B, operational growth ~2% on divestiture-adjusted basis; GAAP revenue declined ~3%","GAAP net loss of $326M ($0.27 diluted loss per share); adjusted EPS $0.69, up ~3% on divestiture-adjusted basis","Adjusted EBITDA $1.2B, up ~2% on same basis; new product revenues $210M in the quarter","Raises 2024 new product revenue guidance to $500M-$600M; expects FY total revenue growth ~2% on divestiture-adjusted operational basis"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":7460000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211005,"accession_number":"0001193125-24-174684","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Viatris closes €1.95B divestiture of over-the-counter business to Cooper Consumer Health","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received €1.85B cash at closing (subject to adjustments) and up to €100M contingent additional consideration.","Buyer paid €25M advance toward transition services fees at closing.","€120M of closing consideration retained by buyer for pending sale of select geography portions.","Transaction closed on July 3, 2024, as previously announced in January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229492,"accession_number":"0001193125-24-152351","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints Dr. Rogério Vivaldi Coelho to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective June 3, 2024; expands Board from 11 to 12 members.","Dr. Vivaldi joins the reestablished Science and Technology Committee.","Former CEO of Sigilon Therapeutics (acquired by Eli Lilly, 2023) and executive at Bioverativ, Spark Therapeutics, and Genzyme.","Led successful approval of more than 15 orphan products across 20+ countries during Genzyme tenure.","Will receive standard compensation for non-employee directors; indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229491,"accession_number":"0001792044-24-000014","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reports strong Q1: revenue $3.66B, adj. EPS $0.67, free cash flow $565M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $3.66B, GAAP net earnings $113.9M; adjusted EBITDA $1.19B; GAAP EPS $0.09, adjusted EPS $0.67.","Fourth consecutive quarter of operational revenue growth on a divestiture-adjusted basis; total sales declined 2% GAAP but grew 2% adjusted.","Closed Idorsia collaboration and Women's Healthcare divestiture; expects API divestiture imminent.","Returned $393M to shareholders in Q1 via dividends and share repurchases; declared quarterly dividend of $0.12 per share.","Reaffirmed 2024 guidance: new product revenue $450-550M; free cash flow target reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":3663400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248035,"accession_number":"0001792044-24-000004","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris FY23 rev $15.4B, adj EBITDA $5.1B; 2024 guidance; $1B buyback boost; Idorsia deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 total revenues $15.4B, U.S. GAAP net earnings $54.7M, adjusted EBITDA $5.1B, free cash flow $2.4B.","Reports third consecutive quarter of operational revenue growth on divestiture-adjusted basis; expects continued growth in 2024.","Enters global R&D collaboration with Idorsia for two Phase 3 assets selatogrel and cenerimod with blockbuster potential.","Board increases share repurchase authorization by $1B to $2B; maintains $0.48 annual dividend, declares $0.12 Q1 dividend.","Completed $250M in share repurchases in 2024 to date; guidance for 2024 provided."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":15426900000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}